Brexit Impact On Drugs - Rising Shortages in UK Highlight Brexit Challenges

Drug shortages in the UK have more than doubled between 2020 and 2023, a recent study by the Nuffield Trust reveals. Brexit is cited as a significant factor exacerbating the country's struggle to mana

BenzingaApr 19 11:39 ET

The protective effect reached 82% after 10 years! Long-term follow-up results of GSK (GSK.US) shingles vaccine announced

The Zhitong Finance App learned that GSK (GSK.US) recently announced its recombinant herpes zoster vaccine Shingrix (RZV), which obtained positive data in the long-term follow-up phase 3 clinical trial ZOSTER-049. The trial tracked participants for about 11 years after receiving Shingrix. The final data showed that RZV was effective in protecting adults over 50 against shingles for more than ten years. Shingles is caused by reactivation of varicella-zoster virus (VZV), which is also the causative agent of chickenpox. Most adults already have this virus in their bodies, and can

Zhitong FinanceApr 18 09:00 ET

Express News | NYSE Order Imbalance 51171.0 Shares on Sell Side

Moomoo 24/7Apr 17 15:50 ET

Analysts Offer Insights on Healthcare Companies: Agilent (A), GlaxoSmithKline (GSK) and Stryker (SYK)

TipRanksApr 17 10:40 ET

GSK Says Its Blockbuster Shingles Vaccine Shows High Efficacy Even After 10 Years

Wednesday, GSK plc (NYSE:GSK) revealed data from the ZOSTER-049 long-term follow-up phase 3 trial, which followed participants for up to approximately 11 years following initial vaccination with Shing

BenzingaApr 17 08:06 ET

GSK's EAGLE-1 Phase 3 Data Show Potential For Gepotidacin As A New Oral Treatment Option For Uncomplicated Urogenital Gonorrhea

Gepotidacin achieved a 92.6% microbiological success rate and was non-inferior to the leading combination treatmentEAGLE-1 is the third positive pivotal trial for gepotidacin, a potential first-in-cla

BenzingaApr 17 05:32 ET